CTAs keep buying Treasuries, gold longs face stop-loss risk: BofA
SAN DIEGO—Peter C. Farrell, Chairman Emeritus and Director at ResMed Inc . (NYSE:RMD), recently sold 2,000 shares of the company’s common stock. The transaction, completed on June 4, 2025, was conducted under a pre-established Rule 10b5-1 trading plan adopted in May 2024. The shares were sold at a price of $247.32 each, totaling $494,640.
Following this sale, Farrell retains ownership of 69,218 shares in the company. This transaction is part of a planned trading strategy, as specified by the Rule 10b5-1 plan.
In other recent news, ResMed has drawn attention from analysts following its third-quarter fiscal year 2025 results. Citi analysts raised the stock price target to AUD45.00, maintaining a Buy rating, after the company’s earnings per share projections improved for fiscal years 2025 to 2027. UBS also reaffirmed a Buy rating with a price target of $285.00, highlighting the potential impact of Apnimed’s new treatment for obstructive sleep apnea, which could influence ResMed’s market position. Meanwhile, Stifel maintained a Hold rating with a $240.00 target, citing concerns about GLP-1 medications and their potential impact on ResMed’s future growth. RBC Capital adjusted its price target to $255.00, maintaining a Sector Perform rating, noting the positive impact of U.S. tariff exemptions on the company’s financials. These developments reflect a mix of optimism and caution among analysts, as they weigh ResMed’s growth prospects against potential market challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.